ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Malignancy"

  • 2015 American Transplant Congress

    Donor-Derived Tumor Transmission Events. A Summary of 2008-2013 Data from the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)

    M. Nalesnik,1 S. Taranto,2 S. Covington,2 E. Blumberg,1 M. Green,1 T. Gross,1 M. Klassen-Fischer,1 M. Pavlakis,1 C. Wolfe,1 D. Kaul.1

    1OPTN Disease Transmission Advisory Committee (DTAC), Richmond, VA; 2United Network for Organ Sharing, Richmond, VA.

    Purpose: Transmission of donor malignancy via transplantation is an uncommon but significant occurrence. The OPTN Disease Transmission Advisory Committee (DTAC) has monitored such complications since…
  • 2015 American Transplant Congress

    Deficiency of Naturally Occurring Anti-Angiogenic Antibodies Associate With the Development of Metastatic Cancer Post Renal Transplantation and Patient Death

    R. Carroll,1 A. Phillippe,2 R. Catar,2 H. Heidecke,2 D. Dragun.2

    1Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; 2Centre for Cardiovascular Research, Charite Hospital, Berlin, Germany.

    We assessed the presence of naturally occurring blocking antibodies to mediators of vascularisation and metastasis in Kidney Transplant Recipients (KTR) with metastatic cancer (n=11), non…
  • 2015 American Transplant Congress

    Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation

    P. De Simone,1 P. Carrai,1 L. Coletti,1 D. Ghinolfi,1 D. Campani,2 F. Filipponi.1

    1Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; 2Pathology, University of Pisa Medical School Hospital, Pisa, Italy.

    Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…
  • 2015 American Transplant Congress

    Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center

    L. Mesa, E. Manzi, M. Valderrama, J. Posada, J. Schweineberg, C. Duran, G. Echeverri, J. Villegas, O. Serrano, L. Caicedo.

    Transplant Unit, Fundación Valle del Lili, Cali, Colombia.

    Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…
  • 2015 American Transplant Congress

    Allo-Stimulated Interferon-γ Release and Natural Killer Cell Function Defines and Risk Stratifies Cancer Development in Kidney Transplant Recipients Who Have Cancer Post-transplantation

    C. Hope,1,2 A. Fuss,1,2 W. Hanf,1 P. Coates,1,2 P. Heeger,3 R. Carroll.1,2

    1The Centre for Clinical and Experimental Transplantation (CCET), Central Northern Adelaide Renal and Transplantation Services (CNARTS), Adelaide, South Australia, Australia; 2Medicine, The University of Adelaide, Adelaide, South Australia, Australia; 3Icahn School of Medicine, The Recanati-Miller Transplant Institute, New York City, NY.

    Reducing immunosuppression is efficacious in primary prevention of cancer in Kidney Transplant Recipients (KTR) but can precipitate graft rejection. Conventional immunosuppressive drug monitoring fails to…
  • 2015 American Transplant Congress

    Early Detection of HCC Mutations in Indeterminate Lesions Using Liquid Biopsies

    Y. Lin,1 K. Cavaness,2 Z. Zhang,1 S. Lin,3 K. Korenblat,1 G. Klintmalm,2 W. Chapman.1

    1Washington University, St. Louis, MO; 2Baylor University, Dallas, TX; 3Stanford University, Palo Alto, CA.

    Background Recent sequencing efforts have characterized the mutation profile of hepatocellular carcinoma (HCC); however, the relevance to clinical decision-making has been limited by the infrequency…
  • 2015 American Transplant Congress

    Risk Factors Influencing Mammography Screening During Kidney Transplant Evaluation

    J. Stoecker, D. Cote, J. Augustine, N. Sarabu, J. Schulak, E. Sanchez, V. Humphreville, J. Ammori, K. Woodside.

    Transplant Institute, University Hospitals & Case Western Reserve University, Cleveland, OH.

    INTRO:Transplant centers typically require mammography (MMG) for women ≥ 40 as part of the evaluation process. The American Cancer Society recommends annual mammograms for the…
  • 2015 American Transplant Congress

    Outcomes of Post-Kidney Transplant Leukemias

    B. Rouphael, A. Kukla, K. Gillingham, H. Ibrahim, A. Matas, N. Issa.

    Medicine, University of Minnesota, Minneapolis, MN.

    Background:Leukemias typically portend bad prognosis in the general population. The incidence and outcomes of post-kidney transplant leukemias (PKTL) have not been well studied as most…
  • 2015 American Transplant Congress

    Unrecognized Synchronous Hepatocellcular Carcinoma Lesions in Explanted Liver Transplant Specimens

    D. Aufhauser, Jr.,1 K. Eddinger,1 E. Furth,2 P. Abt,1 M. Levine.1

    1Department of Surgery, University of Pennsylvania, Philadelphia, PA; 2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.

    Introduction: Liver resection for early-stage hepatocellular carcinoma (HCC) is limited by high surgical risk in cirrhotics and high rates of intrahepatic recurrence. We postulated that…
  • 2015 American Transplant Congress

    Long-Term Survival Outcomes of Liver Transplantation for Klatskin Tumour: A Comparative Study With Radical Resection Surgery

    A. Hu, X. Zhu, X. He.

    Department of general Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

    Background and aim: Besides radical resection (RR), Liver transplantation (LT) is another suggested surgical modality for hilar cholangiocarcinoma (Klatskin tumour, KT) especially for patients whose…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences